When The Braff Group views the entire Outsourced Pharma Services (OPS) universe – Supply Chain, Commercialization, and Clinical Services – current M&A trends look extremely promising. Based on a preliminary review of The Braff Group’s proprietary transaction database through Q2 2026, the sector is on pace for nearly 40% more M&A activity than in 2025 and 17% more than in 2024, the previous banner year holder. Moreover, Q2 2026 deal flow was just a tad below the record set in the second quarter of 2024.
Read the full article: 2026 Clinical Services Mid-Year Update and Outlook //
Source: https://thebraffgroup.com/resource/2026-clinical-services-update/